HemoGenyx Pharmaceuticals Plc (HEMO) Price & Analysis

Compare

37 Followers

HEMO Stock Chart & Stats

568.00p

-12.50p(-3.23%)

At close: Jan 09 4:00 PM EST

568.00p

-12.50p(-3.23%)

Day’s Range― - ―

52-Week Range124.00p - 1,800.00p

Previous CloseN/A

Volume114.00

Average Volume (3M)113.41K

Market Cap

£61.45M

Enterprise Value65.66M

Total Cash (Recent Filing)£226.73K

Total Debt (Recent Filing)£2.20M

Price to Earnings (P/E)―

Beta-0.33

Next Earnings

Apr 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.42

Shares Outstanding6,374,588

10 Day Avg. Volume30,447

30 Day Avg. Volume113,406

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)14.90

Price to Sales (P/S)0.00

P/FCF Ratio-3.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Specialized Therapeutic FocusA clear, narrow focus on hematology and oncology and blood/immune disorders supports durable R&D prioritization and scientific expertise. This specialization can improve trial design, regulatory strategy, and partner interest, sustaining pipeline productivity over months.

Platform Technology OpportunityOwning enabling platform technologies for stem-cell and immune-cell applications creates potential for multiple product derivations, licensing, and collaborations. A reusable platform can generate recurring partners and non-dilutive revenue streams if clinical validation progresses.

Narrowing Operating Cash BurnReduced annual cash burn reflects improved cost control and operational discipline versus prior year. If sustained, lower cash consumption extends runway, reduces near-term financing pressure, and increases the chance management can advance programs further before raising capital.

Bears Say

No RevenueAbsence of any revenue over multiple years signals a pre-revenue R&D stage with no commercial validation yet. This structurally raises execution risk, keeps profitability distant, and makes the company dependent on external financing or partnerships to sustain operations.

Eroding Equity And High LeverageSignificant equity erosion and rising leverage materially weaken the balance sheet, reducing financial flexibility. High debt-to-equity increases likelihood of covenant or refinancing risk and may force dilutive equity raises or limit investment in R&D over the medium term.

Persistent Negative Free Cash FlowContinued negative free cash flow, even if improving, implies ongoing financing needs. Structural negative FCF undermines sustainability absent new revenue or partnership funding, raising the probability of dilution and constraining long-term program advancement and commercialization timelines.

HemoGenyx Pharmaceuticals Plc News

Hemogenyx Raises £2.5m to Advance CAR-T Trials in Adult and Pediatric AML

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has provided an announcement. Hemogenyx Pharmaceuticals has raised £2.5 million from a...

13d ago

Hemogenyx Raises £2.5m to Advance AML CAR-T Trials and Reduce Costs

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) just unveiled an announcement. Hemogenyx Pharmaceuticals has raised £2.5 million through a...

13d ago

Hemogenyx Confirms Updated Share Capital and Voting Rights

An announcement from HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) is now available. Hemogenyx Pharmaceuticals has confirmed that its...

24d ago

Hemogenyx Sets Early January Date for Admission of New Shares

An announcement from HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) is now available. Hemogenyx Pharmaceuticals has confirmed that the...

2M ago

Hemogenyx Pharmaceuticals Announces Equity Issuance and Operational Updates

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) just unveiled an update. Hemogenyx Pharmaceuticals plc has issued 123,377 new ordinary...

2M ago

Hemogenyx Pharmaceuticals Publishes Prospectus for New Share Admission

An announcement from HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) is now available. Hemogenyx Pharmaceuticals has announced the publication...

3M ago

Hemogenyx Pharmaceuticals Advances CAR-T Therapy Trial with DSMB Approval

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has issued an update. Hemogenyx Pharmaceuticals announced that the Data Safety Monitoring...

4M ago

Hemogenyx’s Phase 1 AML Study: A Potential Game-Changer?

Hemogenyx Pharmaceuticals Plc (($GB:HEMO)) announced an update on their ongoing clinical study. Hemogenyx Pharmaceuticals Plc is conducting a...

4M ago

HEMO

Hemogenyx Pharmaceuticals Expands Clinical Trial to Include Pediatric Patients

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) just unveiled an update. Hemogenyx Pharmaceuticals announced that the Institutional Review Board...

5M ago

Hemogenyx Pharmaceuticals Announces Total Voting Rights Update

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has shared an announcement. Hemogenyx Pharmaceuticals announced that its total issued share...

5M ago

HEMO FAQ

What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?

HemoGenyx Pharmaceuticals Plc lowest share price was 124.00p and its highest was 1800.00p in the past 12 months.

What is HemoGenyx Pharmaceuticals Plc’s market cap?

HemoGenyx Pharmaceuticals Plc’s market cap is £61.45M.

When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?

HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date is Apr 24, 2026 which is in 60 days.

How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?

HemoGenyx Pharmaceuticals Plc released its earnings results on Sep 30, 2025. The company reported -1.415p earnings per share for the quarter, missing the consensus estimate of N/A by -1.415p.

Is HemoGenyx Pharmaceuticals Plc overvalued?

According to Wall Street analysts HemoGenyx Pharmaceuticals Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does HemoGenyx Pharmaceuticals Plc pay dividends?

HemoGenyx Pharmaceuticals Plc does not currently pay dividends.

What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?

HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?

HemoGenyx Pharmaceuticals Plc has 6,374,588 shares outstanding.

What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?

HemoGenyx Pharmaceuticals Plc reported an EPS of -1.415p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?

Currently, no hedge funds are holding shares in GB:HEMO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

HemoGenyx Pharmaceuticals Plc Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

-609.30%

Trailing 12-Months

Asset Growth

-49.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.